Global cumulative diagnosis of nearly 100 million vaccine crazy antibody struggle can save the outbreak in the water and fire?

But in the first month of 2021, the outbreak appears to be getting worse.
as of January 25, there were more than 99 million confirmed cases of neo-crown pneumonia worldwide, and the cumulative death toll had reached 2.13 million.
at this rate, the cumulative number of confirmed cases in the coming day may exceed 100 million.
"crazy" vaccine can save the outbreak from fire? 01 Vaccine Madness Looking back, it's not hard to see the "crazy" development of the new crown vaccine.
March 16, 2020, the new crown vaccine sounded the horn of a counterattack.
, the cumulative number of confirmed cases of new crown pneumonia worldwide exceeded 160,000, including 88,000 outside China.
is not optimistic, but it is far from the darkest time compared to the situation that follows.
The outbreak in Europe is beginning to show up, WHO Secretary-General Tan Desse said two days ago that Europe has become the "epicenter" of the new crown pneumonia pandemic, with more confirmed and deadly cases than any other country or region outside China combined, and more new cases per day than at the peak of the epidemic in China.
, the data show that no more than 10,000 cases have been confirmed in any other European country except Italy.
is discussed more about "group immunity" than the closure of the city, the UK government's chief scientific adviser.
a cautious wait-and-see atmosphere pervades the world.
International Olympic Committee (IOC) President Bach said the Tokyo Olympic Games whether to postpone or cancel still need to listen to WHO recommendations.
the United States, fewer than 4,000 cases were confirmed on March 16 (9.86 million confirmed cases were confirmed in the United States on January 25, 2021).
Trump tweeted on March 13 that "the FDA will provide 140 tests next week and add an additional 5 million within a month."
I suspect we don't need that much at all.
", vaccine research and development companies are clearly much more pragmatic than national dignitaries.
day, Moderna injected the first dose of the new crown vaccine into volunteers in Seattle, USA.
there had been widespread predictions that human trials of the new crown vaccine would not take place until April at the earliest.
RNA vaccine, developed by Moderna and the National Institute of Allergy and Infectious Diseases (NIAID), is also the world's first vaccine to enter clinical trials.
63 days, it took Moderna to advance the new coronary vaccine from the gene sequence to clinical trials: the mRNA sequence was confirmed on January 13th, and on February 24th Moderna announced the development of an mRNA vaccine that could be used in the new coronavirus, which was approved for clinical trials by the FDA on March 11th.
to further speed up the process, Moderna even skipped the animal experiment phase and imported it directly into human trials.
moderna's chief medical officer, Tal Zaks, told the media: "I don't think animal models are the key path to bring vaccines into clinical trials.
" preclinical animal trials are often considered a step in screening the drug molecules with the highest chance of success, and Moderna chooses to trade the greater risk of failure for time.
same day, in China, a team of chen Wei academicians in military medical research from the Chinese Academy of Military Sciences and a recombinant new crown vaccine developed by Concino Bio announced that they had been approved for clinical use and began recruiting volunteers.
developed Asia's first recombined Ebola virus disease vaccine.
previous collaborations also led Consino to lead the world into Phase II on April 12.
, Fosun Pharma announced that it had obtained permission from BioNTech of Germany to develop and commercialize vaccine products for COVID-19 based on its proprietary mRNA technology platform in China.
, BioNTech and Pfizer announced a joint development and commercialization agreement for the new crown vaccine in other parts of the world, except China.
first volunteers were recruited in Germany for the BioNTech vaccine clinical trial on April 23.
was loaded by mid-March, but given past progress in vaccine development (8-10 years), vaccines are still thought to take time.
, director of NIAID, said any new crown vaccine under development would take another 12 to 18 months to get into public use, assuming the initial test goes ahead.
the "crazy" of vaccines in a realistic script far exceeded the expectations of Folch or anyone else.
2020, more than four vaccines entered clinical phase III; In November, Pfizer/BioNTech and Moderna Vaccine Phase III trials were more than 90% effective.
December, Pfizer/BioNTech, Moderna, Chinese Medicine, and Coxing Bio were approved for emergency or conditional use around the world.
pandemic has entered the era of vaccines.
, however, the frenzied pace of vaccine development has not put people's lives back on track at the same rate.
is a race against vaccines and viruses, and the virus's madness is no less than vaccines.
U.S. alone, with more than 400,000 deaths and more than 25 million cumulative infections as of January 24.
third outbreak in the United States, which began at the end of 2020, has killed 34,000 people a day from the new coronavirus, and there is no sign of abating.
, an American epidemiologist, said in an interview with the media that the outbreak was a full-scale response with the help of a new variant of the virus, and it was not a time to celebrate.
, on the other hand, vaccinations in the United States are in the dodd of poor execution efficiency.
also began in December, when the U.S. government planned to vaccinate 20 million doses, but the actual dose was less than 5 million.
even without Mr. Trump, american vaccinations would still be difficult and flawed after regime change.
last week, the total number of vaccine distributions in the United States had exceeded 31 million doses, but the actual vaccination rate was less than 40%.
states have been forced to temporarily cancel vaccination appointments because thousands of doses of the vaccine have been badly preserved at low temperatures, U.S. media reported.
problem is not just in the United States.
who recently counted 60 countries and regions around the world have found new variants of the virus in the United Kingdom, and 23 countries have found traces of new variants of the virus from South Africa.
previous study found that only 50 percent of South Africans recovered from antibodies that can identify and defend against a new variant of the virus that changes the shape of the protein, and that the threat from the new variant has spread globally.
the German weekly Mirror said in a cover story titled Variant Virus that the emergence of the variant virus has brought the new crown outbreak into a dangerous phase, the world is facing a new crown outbreak.
slow pace of vaccinations is also troubling the world.
companies say the current capacity simply does not provide enough vaccines the world needs.
Last week, Brazil, South America's worst-hit country, waited for the first vaccine after the death toll exceeded 200,000, with 2 million doses of vaccines produced by Oxford University-mandated Indian pharmaceutical companies and 6 million doses of Koching bio-imported vaccines approved for emergency use.
the world's 49 richest countries snapped up 5.1 billion doses of vaccines because of the unelubic distribution of vaccines caused by inadequate production capacity.
in Africa, vaccine shortages are extremely severe.
only 25 doses of vaccine are available throughout Guinea, which has forced Russia to seek the urgent use of 2 million doses of satellite V, which is still under test.
world is on the brink of catastrophic moral decay, and these first-in-the-nation actions are prolonging the suffering of the new crown pandemic, said Tan Desser, secretary-general of the World Health Organization.
answer can only be more, more vaccines.
02 Why isn't there any medicine? Or, if the vaccine is tight, can therapeutic drugs save the world from a global fire? But the reality is that the absence of new crown drugs remains a challenge for pharmaceutical companies around the world at a time when vaccine research and development are hot and emergency authorizations are in effect.
We all know that the development of new drugs is a long process, an innovative drug from the discovery of targets, target validation to preclinical animal trials, to clinical phase I, II, III, generally need 10-15 years, the cost of more than 1 billion U.S. dollars, can be described as "ten years grinding a sword."
outbreak, "new use of old drugs" has become the mainstream model of global research and development of new crown drugs.
the most notable example is Reed Sive, of Gilead.
October 22, 2020, the FDA officially approved the treatment of new crown patients 12 years of age and weighing more than 40 kg.
, Redsyvir became the world's first new crown drug to be approved.
As early as 2012, Redsivir (compound GS-441524) demonstrated broad-spectrum antiviral capabilities in in-body trials, including hepatitis C, dengue fever, influenza, SARS, norovirus, etc.
was later defeated in the Response to the Ebola outbreak and the trial was completed early in August 2019.
since then, Gilead has not stopped studying Redsyvir's role in other areas, including cat-borne perithitis caused by coronaviruses, where GS-441524 is one of only two treatments in the experimental phase.
thanks to previous trials in the field of antivirals, Redsyvir was listed by researchers as one of the most promising new crown drugs in the early stages of the outbreak, but it was also the most controversial.
week before the FDA approved Redsiway's listing, a WHO study found that Redsiway was invalid.
despite this, Redsiway has shown amazing market potential, with Gilead reporting sales of $785 million in the U.S. and $0.6 billion in the European Union in the first three quarters.
agency forecasts the drug's peak sales of $3,074 million in 2021.
other drugs were not so lucky in a batch of "old drugs for new use" trials.
For example, anti-malaria anti-inflammatory drugs, chloroquine and hydroxychloroquine, which were highly expected early in the outbreak, not only did they not show significant efficacy in the WHO solidarity trial, but in a large UK clinical trial in June, patients who used hydroxychloroquine had even higher mortality rates than the control group (hydroxychloroquine: 25.7 per cent, control group: 23.5 per cent).
addition, two AIDS drugs, Lopinave/Litonave, and β interferon therapy have not achieved significant results.
who had treated Trump for cocktail therapy (2,400 mg dose) was also granted an FDA emergency authorization on November 23, 2020, but must be treated in a hospital or clinic.
antibody cocktail therapy consists of two highly active SARS-CoV-2 meso-antibodies (REGN10933 and REGN10987), in which casirivimab and imdevimab are used to treat adult and mild to moderate neocyclone pneumonia patients, as well as adolescents over 12 years of age with a weight greater than 40 kg.
January 13, U.S. media said the U.S. government would pay as much as $2.6 billion for up to 1.25 million doses of Regeneron's COVID-19 antibody treatment, and that under the agreement the U.S. would buy the lowest dose approved by the FDA (2,400 mg dose).
, the treatment's fourth-quarter sales were $144 million, well below analysts' expectations.
, However, Leonard Schleifer, chief executive of Regeneration, told investors at a recent JP Morgan conference that he expected that number to climb and saw "a lot of demand" for the drug.
also revealed that data on the 1200 mg dose scheme will be submitted in the first quarter of 2021.
same time, the U.S. government announced in December that it plans to buy another 650,000 doses of Lilly's treatment drug bamlanivimab (LY-CoV555) for $812.5 million, the first antibody therapy developed in partnership with Lilly and AbCellera to prevent and treat COVID-19, and was approved by the FDA for emergency use on November 9, 2020.
LY-CoV555 is the first potential new drug specifically targeted at the SARS-CoV-2 virus, according to Lilly.
, there are 125 small molecule drugs in the world that have entered the clinical phase in accordance with the drug development process.
of these, 2 have been approved for listing, 1 application has been submitted for listing, 40 in Phase 3 clinical stage, 68 in Phase 2 clinical phase and 14 phase 1 clinical phase.
three new crown drugs will achieve key results in the first half of 2021, including MERCAD-COVID, Pfizer's NCT04535167, and Roche's NCT04396106, developed in partnership with Atea.
Pfizer is working on a new antiviral drug that has shown potential to fight multiple coronavirus.
END-COVID is a pill developed by Mercadon and Ridgeback to provide options for early treatment outside the hospital.
the same is true of Atea, a prospect that has led the company to one of the best biotech IPOs of 2020 and to a partnership with Roche.
, according to the federal government's database, the Pfizer Phase 1b study could produce results in April, while the interim study data for Merck and Atea therapy could be available in March.
the Chinese side, has earlier approved the treatment of new crown pneumonia in Lianhua Qing plague capsules.
in the research of drugs, as of December 17, China's new crown in the study of drugs for 26, of which in the clinical phase 3 of 5, clinical phase 2 of 8, clinical phase 1 of 12.
the Chinese Academy of Sciences Microbiology institute and Resynants are among the first teams in the world to initiate new coronary and antibody research.
certainly benefited from good control of the domestic outbreak, the latest news stopped in July 2020, Junshi Bio announced a total